

# Study Design

**A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment Naïve Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer That Has High PDL-1 Expression (TPS $\geq$ 50%) and Without Actionable Genomic Alterations (TROPION-LUNG08)**

